COVID‐19 vaccines and their underbelly: Are we going the right way?

Abstract

Abstract Background Historically, a critical aetiological agent of health concern stays till eternity after its discovery, so shall it be with the COVID‐19 outbreak. It has transformed human life to a ‘new normal’ with huge tolls on the social, psychological, intellectual and financial spheres. Aim This perspective aimed to collate numerous reported COVID‐19 vaccine‐associated adverse events and the predisposing factors. It focussed on the efficacy of mix‐n‐match (cocktail) vaccines to effectively counter COVID‐19 infection to facilitate future research and possible interventions. Material and Methods Databases like Scopus, Pubmed and the Web‐of‐science were searched for published literature on ‘adverse events associated with COVID‐19 vaccine’. The reports and updates from health agencies like the WHO and CDC were also considered for the purpose. The details with respect to the adverse events associated with COVID‐19 vaccination and the predisposing factors were compiled to obtain insights and suggest possible future directions in vaccine research. Results India stood strong to manage its health resources in time and turned into a dominant global vaccine supplier at a time when healthcare infrastructure of many countries was still significantly challenged. Developing indigenous vaccines and the vaccination drive in India were its major achievements during the second and the subsequent COVID‐19 waves. The fully indigenous Covaxin vaccine, primarily as an emergency intervention, was successfully rapidly launched. Similar such vaccines for emergency use were developed elsewhere as well. However, all of these reached the marketplace with a ‘emergency use only’ tag, without formal clinical trials and other associated formalities to validate and verify them as these would require much longer incubation time before they are available for human use. Discussion Many adverse events associated with either the first or the second/booster vaccination doses were reported. Evidently, these associated adverse events were considered as ‘usually rare’ or were often underreported. Without the additional financial or ethical burden on the vaccine companies, fortunately, the Phase IV (human) clinical trials of their manufactured vaccines are occurring by default as the human population receives these under the tag ‘emergency use’. Thus, focused and collaborative strategies to unveil the molecular mechanisms in vaccine‐related adverse events in a time‐bound manner are suggested. Conclusion Reliable data particularly on the safety of children is lacking as majority of the current over‐the‐counter COVID‐19 vaccines were for emergency use. Many of these were still in their Phase III and Phase IV trials. The need for a mutant‐proof, next‐gen COVID‐19 vaccine in the face of vaccine‐associated adverse events is opined.

Keywords

• COVID‐19 pandemic
• COVID‐19 vaccine
• efficacy and safety
• vaccine‐associated adverse events